Philippe Gabriel Steg réfléchit sur les résultats de l’étude CANTOS, qui soutient l’hypothèse que l’athérosclérose est une maladie chronique inflammatoire. Il considère que la validation de l’inflammation comme événement critique dans la prévention secondaire des évènements cardiovasculaires ouvre une nouvelle voie thérapeutique.

Educational information

The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.

These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.

Disclosures

Philippe Gabriel Steg, MD - Hôpital Bichat, Paris, France

Funding

Funding to produce this video was provided by an unrestricted educational grant from Novartis.